The potential of predictive analytics to provide clinical decision support in depression treatment planning

Current Opinion in Psychiatry

Volumn 31, Issue 1, 2018, Pages 32-39

  Kessler, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical decision support; Depression; Evidence based psychiatry; Heterogeneity of treatment effects; Personalized medicine

Indexed keywords

CLINICAL DECISION SUPPORT SYSTEM; CLINICAL OBSERVATION; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; PSYCHOTHERAPY; REMISSION; REVIEW; SELF REPORT; TREATMENT PLANNING; TREATMENT RESPONSE; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOLOGY;

ANTIDEPRESSANT AGENT;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DECISION SUPPORT SYSTEMS, CLINICAL; DEPRESSIVE DISORDER, MAJOR; HUMANS; PROSPECTIVE STUDIES; PSYCHOTHERAPY;

EID: 85036649034     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000377     Document Type: Review

References (95)

1. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSMIV major depressive episode. BMC Med 2011; 9:90.
2. Kessler RC. The costs of depression. Psychiatr Clin North Am 2012; 35:1-14.
3. Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry 2017; 210:119-124.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR-D report. Am J Psychiatry 2006; 163:1905-1917.
5. Wells JE, Browne MO, Aguilar-Gaxiola S, et al. Drop out from out-patient mental healthcare in the World Health Organization's World Mental Health Survey Initiative. Br J Psychiatry 2013; 202:42-49.
6. [No authors listed]. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2010; 157:1-45.
7. Malhi GS, Bassett D, Boyce P, et al. Royal australian and new zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087-1206.
8. Parikh SV, Quilty LC, Ravitz P, et al. Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 2. Psychological treatments. Can J Psychiatry 2016; 61:524-539.
9. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry 2016; 61:540-560.
10. Andersson G, Cuijpers P, Carlbring P, et al. Guided Internet-based vs. faceto- face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry 2014; 13:288-295.
11. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med 2013; 10:e1001454.
12. Ruiz FJ. Acceptance and commitment therapy versus traditional cognitive behavioral therapy: a systematic review and meta-analysis of current empirical evidence. Int J Psychol Psychol Ther 2012; 12:333-357.
13. Cuijpers P, Sijbrandij M, Koole SL, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 2013; 12:137-148.
14. Khan A, Faucett J, Lichtenberg P, et al. A systematic review of comparative efficacy of treatments and controls for depression. PLoS One 2012; 7:e41778.
15. Spielmans GI, Berman MI, Usitalo AN. Psychotherapy versus second-generation antidepressants in the treatment of depression: a meta-analysis. J Nerv Ment Dis 2011; 199:142-149.
16. Biesheuvel-Leliefeld KE, Kok GD, Bockting CL, et al. Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and meta-regression. J Affect Disord 2015; 174:400-410.
17. Leichsenring F, Steinert C, Hoyer J. Psychotherapy versus pharmacotherapy of depression: what's the evidence? Z Psychosom Med Psychother 2016; 62:190-195.
18. Barber JP, Muran JC, McCarthy KS, Keefe R. Research on psychodynamic therapies. In: Lambert MJ, editor.Bergin andGarfield's handbook of psychotherapy and behavior change, 6th ed. New York, NY: Wiley; 2013. pp. 443-494.
19. Craighead WE, Dunlop BW. Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. Annu Rev Psychol 2014; 65:267-300.
20. Karyotaki E, Smit Y, Holdt Henningsen K, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 2016; 194:144-152.
21. McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013; 70:821-829.
22. Jha MK, Minhajuddin A, Gadad BS, et al. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: covel T cell biomarker for antidepressant medication selection. Brain Behav Immun 2017; https://doi.org/10.1016/j.bbi.2017.07.005. [Epub ahead of print]
23. Huibers MJ, Cohen ZD, Lemmens LH, et al. Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach. PLoS One 2015; 10:e0140771.
24. Harald B, Gordon P. Meta-review of depressive subtyping models. J Affect Disord 2012; 139:126-140.
25. van Loo HM, de Jonge P, Romeijn JW, et al. Data-driven subtypes of major depressive disorder: a systematic review. BMC Med 2012; 10:156.
26. Arns M, Gordon E, Boutros NN. EEG abnormalities are associated with poorer depressive symptom outcomes with escitalopram and venlafaxine-XR, but not sertraline: results from the multicenter randomized iSPOT-D Study. Clin EEG Neurosci 2017; 48:33-40.
27. Cuijpers P, Reynolds CF 3rd, Donker T, et al. Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depress Anxiety 2012; 29:855-864.
28. Thase ME. Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci 2014; 16:539-544.
29. Fabbri C, Hosak L, Mossner R, et al. Consensus paper of the WFSBP Task Force on Genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry 2017; 18:5-28.
30. Sutton TA, Sohrabi HR, Rainey-Smith SR, et al. The role of apoe-varepsilon4 and beta amyloid in the differential rate of recovery from ECT: a review. Transl Psychiatry 2015; 5:e539.
31. Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 2015; 16:7796-7801.
32. Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 2015; 25:1532-1543.
33. Chan MK, Cooper JD, Bot M, et al. Blood-based immune-endocrine biomarkers of treatment response in depression. J Psychiatr Res 2016; 83:249-259.
34. Gadad BS, Jha MK, Grannemann BD, et al. Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: findings from the co-med trial. J Psychiatr Res 2017; 94:1-6.
35. Olbrich S, van Dinteren R, Arns M. Personalized medicine: review and perspectives of promising baseline EEG biomarkers in major depressive disorder and attention deficit hyperactivity disorder. Neuropsychobiology 2015; 72:229-240.
36. Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 2017; 23:28-38.
37. Phillips ML, Chase HW, Sheline YI, et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 2015; 172:124-138.
38. Frodl T. Recent advances in predicting responses to antidepressant treatment. F1000Res 2017; 6:619.
39. Gadad BS, Jha MK, Czysz A, et al. Peripheral biomarkers of major depression and antidepressant treatment response: current knowledge and future outlooks. J Affect Disord 2017; https://doi.org/10.1016/j.jad.2017.07.001. [Epub ahead of print]
40. Nassan M, Nicholson WT, Elliott MA, et al. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin Proc 2016; 91:897-907.
41. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 2017; 78:720-729.
42. Bousman CA, Forbes M, Jayaram M, et al. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry 2017; 17:60.
43. Trivedi MH, McGrath PJ, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psychiatr Res 2016; 78:11-23.
44. Kessler RC, van Loo HM, Wardenaar KJ, et al. Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatr Sci 2017; 26:22-36.
45. De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of nonresponse/nonremission in treatment resistant depressed patients: a systematic review. Psychiatry Res 2016; 240:421-430.
46. von Wolff A, Holzel LP, Westphal A, et al. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: a systematic review and meta-analysis. BMC Psychiatry 2012; 12:61.
47. Jobst A, Brakemeier EL, Buchheim A, et al. European Psychiatric Association guidance on psychotherapy in chronic depression across Europe. Eur Psychiatry 2016; 33:18-36.
48. Bausch P, Fangmeier T, Zobel I, et al. The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: a secondary analysis. Clin Psychol Psychother 2017; 24:1155-1162.
49. Harkness KL, Bagby RM, Kennedy SH. Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. J Consult Clin Psychol 2012; 80:342-353.
50. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003; 100:14293-14296.
51. Ebert DD, Donkin L, Andersson G, et al. Does Internet-based guided-self-help for depression cause harm? An individual participant data meta-analysis on deterioration rates and its moderators in randomized controlled trials. Psychol Med 2016; 46:2679-2693.
52. Dawson EL, Caveney AF, Meyers KK, et al. Executive functioning at baseline prospectively predicts depression treatment response. Prim Care Companion CNS Disord 2017; 19:; https://doi.org/10.4088/PCC.16m01949. [Epub ahead of print]
53. Pimontel MA, Culang-Reinlieb ME, Morimoto SS, Sneed JR. Executive dysfunction and treatment response in late-life depression. Int J Geriatr Psychiatry 2012; 27:893-899.
54. Gordon E, Rush AJ, Palmer DM, et al. Toward an online cognitive and emotional battery to predict treatment remission in depression. Neuropsychiatr Dis Treat 2015; 11:517-531.
55. Clever SL, Ford DE, Rubenstein LV, et al. Primary care patients' involvement in decision-making is associated with improvement in depression. Med Care 2006; 44:398-405.
56. Lin P, Campbell DG, Chaney EF, et al. The influence of patient preference on depression treatment in primary care. Ann Behav Med 2005; 30:164-173.
57. Waltz TJ, Campbell DG, Kirchner JE, et al. Veterans with depression in primary care: urovider preferences, matching, and care satisfaction. Fam Syst Health 2014; 32:367-377.
58. Dunlop BW, Kelley ME, Aponte-Rivera V, et al. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Am J Psychiatry 2017; 174:546-556.
59. Ebert DD, Berking M, Cuijpers P, et al. Increasing the acceptance of Internetbased mental health interventions in primary care patients with depressive symptoms. A randomized controlled trial. J Affect Disord 2015; 176:9-17.
60. Jha MK, Teer RB, Minhajuddin A, et al. Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatr Dis Treat 2017; 13:803-813.
61. Lipkovich I, Dmitrienko A, D'Agostino BR Sr. Tutorial in biostatistics: datadriven subgroup identification and analysis in clinical trials. Stat Med 2017; 36:136-196.
62. Luedtke AR, van der Laan MJ. Optimal individualized treatments in resourcelimited settings. Int J Biostat 2016; 12:283-303.
63. Petkova E, Ogden RT, Tarpey T, et al. Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study. Contemp Clin Trials Commun 2017; 6:22-30.
64. Zhao Y, Zeng D, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. J Am Stat Assoc 2012; 107:1106-1118.
65. Sung SC, Wisniewski SR, Balasubramani GK, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A co-med trial report. Psychol Med 2013; 43:945-960.
66. Uher R, Maier W, Hauser J, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009; 194:252-259.
67. Lorenzo-Luaces L, DeRubeis RJ, van Straten A, Tiemens B. A prognostic index (PI) as a moderator of outcomes in the treatment of depression: a proof of concept combining multiple variables to inform risk-stratified stepped care models. J Affect Disord 2017; 213:78-85.
68. Cuijpers P, Weitz E, Lamers F, et al. Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. Depress Anxiety 2017; 34:246-256.
69. Vittengl JR, Jarrett RB, Weitz E, et al. Divergent outcomes in cognitivebehavioral therapy and pharmacotherapy for adult depression. Am J Psychiatry 2016; 173:481-490.
70. Judd CM, Westfall J, Kenny DA. Experiments with more than one random factor: designs, analytic models, and statistical power. Annu Rev Psychol 2017; 68:601-625.
71. Smith GC, Seaman SR, Wood AM, et al. Correcting for optimistic prediction in small data sets. Am J Epidemiol 2014; 180:318-324.
72. GENDEP Investigators; MARS Investigators; STAR-D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170:207-217.
73. Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 2015; 5:e553.
74. Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev 2017; https://doi.org/10.1016/j.neubiorev.2017.08.019. [Epub ahead of print]
75. Paganini S, Teigelkotter W, Buntrock C, Baumeister H. Economic evaluations of internet- and mobile-based interventions for the treatment and prevention of depression: A systematic review. J Affect Disord 2018; 225:733-755.
76. Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. J Psychiatr Pract 2013; 19:204-212.
77. Ebert DD, Heber E, Berking M, et al. Self-guided Internet-based and mobilebased stress management for employees: results of a randomised controlled trial. Occup Environ Med 2016; 73:315-323.
78. Ebert DD, Lehr D, Smit F, et al. Efficacy and cost-effectiveness of minimal guided and unguided Internet-based mobile supported stress-management in employees with occupational stress: a three-armed randomised controlled trial. BMC Public Health 2014; 14:807.
79. Kenter RM, Cuijpers P, Beekman A, van Straten A. Effectiveness of a webbased guided self-help intervention for outpatients with a depressive disorder: short-term results from a randomized controlled trial. J Med Internet Res 2016; 18:e80.
80. Klein JP, Spath C, Schroder J, et al. Time to remission from mild to moderate depressive symptoms: one year results from the evident-study, an RCT of an Internet intervention for depression. Behav Res Ther 2017; 97:154-162.
81. Rethorst CD, South CC, Rush AJ, et al. Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. Depress Anxiety 2017; https://doi.org/10.1002/da.22670. [Epub ahead of print]
82. Dorresteijn JA, Visseren FL, Ridker PM, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011; 343:d5888.
83. Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic brain injury. BMC Med Inform Decis Mak 2006; 6:38.
84. Prieto-Merino D, Pocock SJ. The science of risk models. Eur J Prev Cardiol 2012; 19:7-13.
85. Luedtke AR, van der Laan MJ. Evaluating the impact of treating the optimal subgroup. Stat Methods Med Res 2017; 26:1630-1640.
86. van der Laan M, Rose S. Targeted learning: causal inference for observational and experimental data. New York, NY: Springer; 2011.
87. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014; MR000034.
88. Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics 2017; 14:716-727.
89. Garay RP, Zarate CA Jr, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother 2017; 17:593-609.
90. Ge R, Blumberger DM, Downar J, et al. Abnormal functional connectivity within resting-state networks is related to RTMS-based therapy effects of treatment resistant depression: a pilot study. J Affect Disord 2017; 218:75-81.
91. Njau S, Joshi SH, Espinoza R, et al. Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J Psychiatry Neurosci 2017; 42:6-16.
92. Papadimitropoulou K, Vossen C, Karabis A, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33:701-711.
93. Schuster MA, Onorato SE, Meltzer DO.Measuring the cost of quality measurement: a missing link in quality strategy. JAMA 2017; 318:1219-1220.
94. Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry 2015; 172:1004-1013.
95. Hallgren KA, Bauer AM, Atkins DC. Digital technology and clinical decision making in depression treatment: current findings and future opportunities. Depress Anxiety 2017; 34:494-501.